Janus Henderson Group PLC Sells 308,844 Shares of Penumbra, Inc. $PEN

Janus Henderson Group PLC decreased its position in Penumbra, Inc. (NYSE:PEN) by 64.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 167,054 shares of the company’s stock after selling 308,844 shares during the quarter. Janus Henderson Group PLC’s holdings in Penumbra were worth $54,849,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of PEN. Amundi grew its stake in shares of Penumbra by 302.9% in the first quarter. Amundi now owns 345,758 shares of the company’s stock worth $113,537,000 after purchasing an additional 259,936 shares during the last quarter. California State Teachers Retirement System lifted its holdings in Penumbra by 22.2% in the 1st quarter. California State Teachers Retirement System now owns 42,987 shares of the company’s stock worth $14,116,000 after buying an additional 7,800 shares during the period. Empyrean Capital Partners LP purchased a new stake in Penumbra in the 1st quarter worth approximately $27,911,000. Quantinno Capital Management LP grew its position in shares of Penumbra by 6.7% in the 1st quarter. Quantinno Capital Management LP now owns 13,641 shares of the company’s stock worth $4,480,000 after buying an additional 851 shares during the last quarter. Finally, Whitebox Advisors LLC bought a new stake in shares of Penumbra in the 1st quarter worth approximately $146,125,000. 88.88% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

PEN has been the subject of a number of recent analyst reports. Citigroup decreased their target price on Penumbra from $374.00 to $350.00 and set a “neutral” rating for the company in a report on Thursday, May 7th. Zacks Research downgraded shares of Penumbra from a “hold” rating to a “strong sell” rating in a research report on Monday, June 29th. Royal Bank Of Canada restated a “sector perform” rating and issued a $374.00 price objective on shares of Penumbra in a report on Thursday, June 11th. Wall Street Zen raised shares of Penumbra to a “hold” rating in a research report on Saturday, May 9th. Finally, Evercore reaffirmed an “outperform” rating and set a $320.00 target price on shares of Penumbra in a research note on Monday, July 6th. Three analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $367.07.

Penumbra Trading Up 0.5%

NYSE PEN opened at $321.40 on Friday. The firm has a market capitalization of $12.64 billion, a PE ratio of 78.97, a P/E/G ratio of 1.99 and a beta of 0.70. The stock’s 50 day moving average is $318.75 and its 200 day moving average is $330.03. Penumbra, Inc. has a twelve month low of $221.26 and a twelve month high of $362.41. The company has a quick ratio of 3.95, a current ratio of 6.02 and a debt-to-equity ratio of 0.01.

Penumbra (NYSE:PEN) last posted its quarterly earnings data on Thursday, July 30th. The company reported $0.88 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.28). Penumbra had a return on equity of 10.70% and a net margin of 10.67%.The firm had revenue of $390.05 million during the quarter, compared to the consensus estimate of $389.64 million. During the same quarter last year, the company posted $0.86 EPS. Penumbra’s revenue for the quarter was up 14.9% compared to the same quarter last year. Research analysts forecast that Penumbra, Inc. will post 5.02 earnings per share for the current fiscal year.

Penumbra Profile

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.